Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20278030 | 1.00 | CYP3A4 (0.33) | CYP3A4NR3C1SHBGMAPTALOX15 | |
| SCHEMBL12162287 | 0.90 | CYP3A4 (0.35) | CYP3A4NR3C1SHBGMAPTALOX15 | |
| SCHEMBL13706117 | 0.78 | — | — | |
| SCHEMBL4235455 | 0.75 | — | — | |
| SCHEMBL12179478 | 0.71 | ESR1 (0.31) | — | |
| SCHEMBL16842368 | 0.70 | MAPT (0.30) | MAPT | |
| SCHEMBL267390 | 0.69 | NR3C1 (0.41) | CYP3A4NR3C1SHBG | |
| SCHEMBL11636367 | 0.69 | NR3C1 (0.41) | CYP3A4NR3C1SHBG | |
| SCHEMBL1880354 | 0.69 | NR3C1 (0.41) | CYP3A4NR3C1SHBG | |
| SCHEMBL2502530 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11465963-B2 | Tetrahydronaphthalene derivatives useful as Nrf2 activators | BIOGEN MA INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20200299230-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES USEFUL AS NRF2 ACTIVATORS | BIOGEN MA INC. | 2020-09-24 | — | — | US | disclosed |
| WO-2019104030-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES USEFUL AS NRF2 ACTIVATORS | BIOGEN MA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299230-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES USEFUL AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | CYP3A4 265/4885NR3C1 486/4885SHBG 3405/4885 |
| US-11465963-B2 | Tetrahydronaphthalene derivatives useful as Nrf2 activators | NFE2L2, KEAP1, NQO1 | CYP3A4 265/4885NR3C1 486/4885SHBG 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.